산과영역에서 수혈거부 환자의 무수혈적 치료에 대한 임상적 고찰
Clinical analysis of non-blood transfusion treatment in patients who refuseda blood transfusion for obstetrical part
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objective: The goal of this study is to analyze the clinical manifestation of obstetrical patients who refused transfusion of any blood component. Through this analysis, we could define the guideline of non-blood transfusion treatment during the obstetrical procedure. Methods: 127 patients who visited our non-blood transfusion treatment center and had obstetrical procedures from 1 Jan. 2000 to 31 March 2006 participated in this study. They were retrospectively analyzed according to the following indexes; the reason of refusing blood transfusion, age, ratio of vaginal delivery to Cesarean section, comparison of hemoglobin level, volume of blood loss, presence of bloodless treatment, days of hospitalization, presence of blood transfusion, consequence of patient (including complications and deaths). Bloodless treatment at the hospital are medical method (recombinant human erythropoietin, Aprotinin, Hemocoagulase, Tranexamine acid, Venoferrum), Autotransfusion and Electrocauterization. Results: Among 126 patients (except for 1 patient who was delivered at the other hospital), the vaginal delivery group consisted of 57, and the Cesarean operation group was 69. The most common cause of primary caesarean section was arrest disorder of cephalo-pelvic disproportion. Among 26 patients qualified for indication of transfusion, uterine atony had the highest number of patients at 16. Among the indication of transfusion, low hemoglobin level (≦8.0 g/dL) after operation had the highest number of patients at 20. Patients qualified indication of transfusion had twice more blood loss (464.6±34.2 ml vs 920.5±214.2 ml) and two more days of hospitalization (7.6±0.5 day vs 9.7±0.6 day) compared with those of non-qualified for indication of transfusion. Nobody received direct transfusion of blood component. There were no death but acute renal failure in one patient, and DIC (disseminated intravascular coagulation) in another patient as complications. Conclusions: This study analyzed the clinical manifestations of patients who refused a blood transfusion in obstetrics. Especially, when the non-blood transfusion treatment was performed, which had been an issue in recent times, more active treatment showed less reduction of hemoglobin level than no treatment. This study also confirmed that bleeding patients can be treated by selective non-blood transfusion treatment.
Abstract
Objective: The goal of this study is to analyze the clinical manifestation of obstetrical patients who refused transfusion of any blood component. Through this analysis, we could define the guideline of non-blood transfusion treatment during the obstetrical procedure. Methods: 127 patients who visited our non-blood transfusion treatment center and had obstetrical procedures from 1 Jan. 2000 to 31 March 2006 participated in this study. They were retrospectively analyzed according to the following indexes; the reason of refusing blood transfusion, age, ratio of vaginal delivery to Cesarean section, comparison of hemoglobin level, volume of blood loss, presence of bloodless treatment, days of hospitalization, presence of blood transfusion, consequence of patient (including complications and deaths). Bloodless treatment at the hospital are medical method (recombinant human erythropoietin, Aprotinin, Hemocoagulase, Tranexamine acid, Venoferrum), Autotransfusion and Electrocauterization. Results: Among 126 patients (except for 1 patient who was delivered at the other hospital), the vaginal delivery group consisted of 57, and the Cesarean operation group was 69. The most common cause of primary caesarean section was arrest disorder of cephalo-pelvic disproportion. Among 26 patients qualified for indication of transfusion, uterine atony had the highest number of patients at 16. Among the indication of transfusion, low hemoglobin level (≦8.0 g/dL) after operation had the highest number of patients at 20. Patients qualified indication of transfusion had twice more blood loss (464.6±34.2 ml vs 920.5±214.2 ml) and two more days of hospitalization (7.6±0.5 day vs 9.7±0.6 day) compared with those of non-qualified for indication of transfusion. Nobody received direct transfusion of blood component. There were no death but acute renal failure in one patient, and DIC (disseminated intravascular coagulation) in another patient as complications. Conclusions: This study analyzed the clinical manifestations of patients who refused a blood transfusion in obstetrics. Especially, when the non-blood transfusion treatment was performed, which had been an issue in recent times, more active treatment showed less reduction of hemoglobin level than no treatment. This study also confirmed that bleeding patients can be treated by selective non-blood transfusion treatment.
참고문헌 (24)
- Ramos HC, "Liver transplantation without the use of blood product", Arch Surg, 129, pp.528~532 (1994)
- Clarke JM, "Surgery in Jehovah’s Witnesses", Br. J Hospital Med, 27, pp.497~500 (1982)
- Coll CE, "Care of Jehovah’s Witnesses", Anaesthesia, 39, pp.497~498 (1984)
- Thomas JM, "Meeting the surgical and ethical challenge presented by Jehovah’s Witness", Can Med Assoc J, 128, pp.1153~1154 (1983)
- How WG, "Treatment of Jehovah’s Witnesses", Can Med Assoc J, 130, pp.253~256 (1984)
- Samra SK, "A study of blood utilization in association with hysterectomy", Transfusion, 23, pp.490~495 (1983)
- McVay PA, "Safety and use of autologous blood donation during the third trimester of pregnancy", Am J Obstet Gynecol, 160, pp.1479~1488 (1989)
- Cundy JM, "Jehovah’s Witnesses and haemorrhage", Anaesthesia, 35, pp.1013~1014 (1980)
- Khine HH, "A method of blood conservation in Jehovah’s Witnesses: incirculation diversion and refusion", Anesth Analg, 57, pp.279~280 (1978)
- Lichtiger B, "Hemotherapy during surgery for Jehovah’s Witnesses: a new method", Anesth Analg, 61, pp.618~619 (1982)
- Cunningham AJ, "Controlled hypotension to minimize blood loss of anemic Jehovah’s Witness patient undergoing total hip and shoulder replacement", Br J Anaesth, 54, pp.895~898 (1982)
- Thomas GI, "Some issues involved with major surgery on Jehovah’s Witness", Am Surg, 34, pp.538~544 (1968)
- Dixon JL, "Jehovah’s Witnesses. the surgical", ethical challenge, 1981, pp.246, 2471~2472
- Byrne MP, "Abdominal aortic aneurysm surgery in the Jehovah’s Witness. Use of auto transfusion use of autotransfusion", IMJ Ill Med J, 150, pp.87~90 (1976)
- Ottesen S, "Use of haemonetics cell saver for autotransfusion in cardiovascular surgery", Scand J Thorac Cardiovasc Surg, 16, pp.263~268 (1982)
- Ott DA, "Cardiovascular surgery in Jehovah's Witnesses. Report of 542 operations without blood transfusion", JAMA, 238, pp.1256~1258 (1977)
- Dorsey JS, "Emergency portacaval shunting in Jehovah’s Witnesses", Can J Surg, 23, pp.197~198 (1980)
- Bricker DL, "Repair of acute dissection of the ascending aorta, associated with coarctation of the thoracic aorta in a Jehovah’s Witness", J Cardiovasc Surg (Torino), 21, pp.374~378 (1980)
- Clark SC, "The human hematopoietic colony-stimulating factors", Science, 236, pp.1229~1237 (1987)
- Winearls CG, "Effect of human erythropoietin derived form recombinant DNA on the anemia of patients maintained by chronic hemodialysis", Lancet, 2, pp.1175~1178 (1986)
- Nearman HS, "Postoperative management of a severely anemic Jehovah’s Wittness", Crit Care Med, 11, pp.142~143 (1983)
- Means RT Jr, "Progress in understanding the pathogenesis of the anemia of chronic disease", Blood, 80, pp.1639~1647 (1992)
- Wurnig C, "Subcutaneous low-dose epoetin beta for the avoidance of transfusion in patients scheduled for elective surgery not eligible for autologous blood donation", Eur Surg Res, 33, pp.303~310 (2001)
- Cascinu S, "Cisplatin - associated anemia treated with subcutaneous erythropoietin", A pilot study. Br J Cancer, 67, pp.156~158 (1993)